InvestorsHub Logo
icon url

ohm20

02/20/20 7:01 PM

#56967 RE: RealinvestDD #56943

Shorting 600 million market cap company with no approval and no revenue is a good things


It's like you don't know that catalysts drive biopharma share prices and Cytodyn has large upcoming catalysts.

Even sometimes after the fda approval the stock will wait for revenue results


What happens there is that the stock is highly oversold prior to FDA approval compared to what the actual revenue will be. AGRX being the most current example. With Cytodyn's long pipeline that shouldn't be a problem unless it shoots to $10+ that early. With BTD and continued advancement in the cancer indication even that price might not be a problem.
icon url

ohm20

02/20/20 10:23 PM

#56973 RE: RealinvestDD #56943

Shorting 600 million market cap company with no approval and no revenue is a good things


But where's the billion shares?

Say hello to one billion shares outstanding by next year RIDD (2018)


and 15 cents?

As I said going to be 0.15c RIDD (2018)


icon url

Bobbyinvest

02/20/20 10:39 PM

#56976 RE: RealinvestDD #56943

Genius MC is no longer $600 Million it’s $471 as of close today.